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1. Introduction 
Maroteaux-Lamy s ndrome (Mucopolysacchari- 
dosis VI) is characterized by excessive deposition i  
tissues and excretion of dermatan sulphate. Although 
it has been shown in several laboratories that the 
activity of arylsulphatase B is diminished in the 
patient's serum, urine and fibroblasts [ I -5] ,  the 
enzymatic basis of the metabolic defect has not been 
completely resolved. According to Matalon et al. [6] 
the marked iminution of sulphate release from 
[3SS]chondroitin-4-SO4 and [ass]heptasaccharide, 
which were extracted from fibroblasts with Maroteaux- 
Lamy syndrome may be due to chondroitin sulphate- 
N-acetylgalactosamine-4-sulphate sulphatase deficiency. 
The same conclusion was reached by O'Brien et al. 
[7] on the basis of the chemical structure analysis 
of a degradation product of dermatan sulphate 
derived from Maroteaux-Lamy fibroblasts. In a very 
recent work, Stumpf et al. [8] reported that UDP-N- 
acetylgalactosamine-4-sulphate might serve as substrate 
for arylsulphatase B. 
The results presented in this paper suggest that 
although arylsulphatase B may be identical to 
Maroteaux-Lamy corrective factor, it is only a part 
of an enzyme system required for sulphate release 
from mucopolysaccharide fragments invitro. 
*To whom reprint requests hould be addressed. 
North-Holland Publishing Company - Amsterdam 
2. Materials and methods 
2.1. Materials 
The reagents A-4S-disaccharide, A-6S-disaccharide 
and chondroitinase A, B and C (lot 7204) were 
obtained from Seikagaku Fine Biochem., Japan; 
Resin AG-1 X 8 (400 mesh C1- form) was obtained 
from Bio-Rad Laboratories, USA; Ampholine 
(pH 5.0-8.0) was obtained from LKB, Sweden; 
Nitrocatechol sulphate (dipotassium salt) and 
glucuronolactone w re obtained from Sigma Chemical 
Corporation, St. Louis, USA, while Dextran Blue 2000. 
Dextran 10 000, Dextran 20 000, Sephadex G-50 
and Sephadex G-IO were from Pharmacia Fine 
Chemicals, Uppsala, Sweden; Chondroitin-6-sulphate 
was from Miles, Labs, Elkhart, Indiana, USA; Heparin 
was from Boots Pure drug Co. Ltd, Nottingham, 
England and dermatan sulphate (Ro 1-2232/715) was 
a gift of Dr K. Von Berlepsh from Hoffmann-La 
Roche Laboratories, Switzerland. 
2.2. Methods 
Digestion of dermatan sulphate by chondroitinase 
A, B and C. Digestion of 10 mg of dermatan sulphate 
was carried out with one unit of chondroitinase A, B 
and C at 37°C for 24 h in 0.5 M Tris-acetate buffer, 
pH 8.1, in a total volume of 2 ml. Digestion of 10 mg 
of high molecular weight glycosaminoglycans 
(prepared according to the procedure of Di Ferrante 
et al. [9] ), from urine of individuals with Maroteaux- 
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Fig.1. Isoelectric focusing of placental arylsulphatase 
Ba, fl, ~.. The LKB isoelectric focusing column was filled 
according to Vesterberg [17]. A total of 20 mg of arylsul- 
phatase B~, ~ "r (specific activity, 6.1 #tool of nitrocatechol 
converted min -1 mg -1 ) were applied to an isoelectric 
focusing column (110 ml). Focusing was performed in 
pH 5.0-8.0 ampholines at 2°C and 500 V with a starting 
current of 12 mA. At the end of the experiment, 1.5 ml 
fractions were collected. Arylsulphatase B activity was 
determined using a 5 #1 aliquots of each fraction in a 5 min 
incubation at 37°C with 10 mM nitrocatechol sulphate in 
0.5 M sodium acetate, pH 5.8. Protein concentration was 
monitored at 280 nm and pH measured with a Corning 
Model 7 pH meter at 20°C. 
Lamy syndrome, was carried out under identical 
conditions. The degradation products as well as 
A-4S-disaccharides and inorganic sulphate were 
separated on AG 1 X 8 ion exchanger column as 
described under fig.3. The primary product of 
degradation of dermatan sulphate was eluted with 
0.9 N NaCI. The two degradation products obtained 
from urine of Maroteaux-Lamy affected individual 
were eluted at 0.7 and 1.2 N NaC1. The main degrada- 
tion product of dermatan sulphate and the two 
fractions from Maroteaux-Lamy mucopolysaccharide 
were collected, concentrated and desalted on Sephadex 
G-10 column (2.8 X 70 cm). 
Molecular weight determinations were carried out 
by gel filtration on Sephadex G-50 (fine); 0.9 × 110 
cm column. Molecular weight standards included: 
nitrocatechol sulphate (mol. wt. 311), A-6S-disac- 
charide (mol. wt. 397), dextran 10 000 and 20 000, 
heparin (mol. wt. 11 000), dermatan sulphate 
(mol. wt. 27 000). 
Polyacrylamide gel electrophoresis was performed 
according to the procedure of Weber et al. [10]. 
Arylsulphatase B activity was measured in 0.5 M 
acetate buffer, pH 5.8, using 10 mM 2-hydroxy-5- 
nitrocatechol sulphate as the substrate, according to 
the procedure of Robinson et al. [11 ]. 
Sulphate content was quantitated by the Dodgson 
procedure [12]. For estimation of total sulphate, 
the sample was hydrolysed in 0.25 N performic acid 
(100°C, 12 h) prior to determination. Uronic acid 
content was determined by the procedure of Wardi 
et al. [13]. Protein content was estimated by the 
method of Warburg and Christian [ 14]. 
Tissue culture experiments were performed as 
described by Di Ferrante et al. [15]. 
Arylsulphatase B from human placenta was 
prepared by the procedure of Gniot-Szulzycka [16] 
and subfractionated by isoelectrofocusing [17]. 
U.v. spectra were recorded on Beckman spectro- 
photometer; CD spectra for dermatan sulphate, 
octasaccharide and A-4S-disaccharide were measured 
on Cary 61 spectropolarimeter. The mean residue 
ellipticity, [O], was calculated according to the 
equation: 
II III IV V Vl VII 
Fig.2. Acrylamide gel electrophoresis pattern of subfractions 
after isoelectric focusing. Electrophoresis was carried out at 
pH 7.8 in 5% polyacrylamide g ls (8 mA/tube, 6 h), according 
to the procedure of Weber et al. [ 10]. 100 gg of protein were 
applied to each gel. Gels were stained for protein with 
Comassie briUant blue and destained in 5% acetic acid. 
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Table 1 
Arylsulphatase B activity and corrective activity in tissue culture of different subtractions after isoelectric focusing 
Fraction I II III IV V VI VII Total 
pl - 8.1 7.4 7.0 6.3 6.0 4.6 - 
Total arylsulphatase B 
activity (nM of nitrocatechol 
per min) 70 8640 308 200 0 0 0 9220 
Specific activity (#moles 
of nitrocatechol per mg 
protein per min) 0.04 21.6 13.6 0.8 . . . .  
Percent of maximal correction 
in the presence of 75 tzg of 
protein a 0 60 19 14 . . . .  
a 72 h a2SO, uptake of patient's fibroblasts in the presence of 75 t~g of different subfractions after isoelectric 
focusing was measured. 
OXMRW 
[O1 - 10 Ic 
where MRW is the mean residue weight, O is the 
measured ellipticity at wavelength 2~, c concentration 
in g/ml and 1 is the cell path length in cm (18). 
4. Results and discussion 
Seven different subfractions have been obtained 
after isoelectrofocusing of human placental arylsul- 
phatase Ba,/~, ~, (specific activity of 6/amol of nitro- 
catechol sulphate converted to nitrocatechol per min 
per mg of protein). Table I shows that in addition to 
the most active subfraction (II), subfractions I, III 
and IV revealed arylsulphatase activity after a 1 h 
incubation of the assay mixture. Fractions V, VI and 
VII did not exhibit any arylsulphatase B activity. The 
overall recovery of the enzymatic activity and protein 
was 50% and 73%, respectively. Two protein bands 
were present in all but one of the subfractions as 
demonstrated by polyacrylamide gel electrophoresis. 
The most highly purified subfraction (II), specific 
activity 21/amol nitrocatechol produced per rnin per 
mg protein (both protein bands were active), revealed 
the highest corrective activity (table 1). These data 
strongly suggest hat the missing factor in Maroteaux- 
Lamy syndrome is identical to arylsulphatase B.
The highly purified subfraction of arylsulphatase 
B, contrary to the less purified enzyme, did not 
hydrolyse the mucopolysaccharide fragments which 
were obtained by digestion of dermatan sulphate by 
chondroitinase A, B and C and which eluted from 
AG 1 X 8 ion exchanger with 0.9 N NaC1 (fig.3). The 
digestion product of chondroitinase A, B and C, 
according tothe literature [19], should contain 
A-4S-disaccharide which should be eluted with 0.4 N 
NaC1 from AG 1 X 8 resin. 
However, the degradation product of dermatan 
sulphate Ro-1-2232/715 by chondroitinase A, B and 
C respectively gave a product which eluted with 0.9 N 
NaCI and had a mol. wt. of approx. 1600 (fig.4). The 
ratio of hexosamine, uronic acid and sulphate was 
1.0 : 1.04 : 0.55. These data suggest hat the degrada- 
tion product is an octasaccharide. The CD spectrum 
for the octasaccharide (fig.5) appeared to be different 
to that for A-4S-disaccharide. Fig.6 shows u.v. spectra 
for octasaccharide, desulphated octasaccharide and 
dermatan sulphate. 
The ability for sulphate release from this octa- 
saccharide substrate can be restored by combining 
the subfraction with arylsulphatase B activity (pI = 
8.1) with fractions containing no arylsulphatase B 
activity. The most active complementary subfraction 
had an isoelectric point of 6.0. From the octasac- 
charide substrate containing 24/ag of sulphate, 75% 
of the sulphate was released after incubation with 
1.85/ag of subfraction II and 4/ag protein of subfrac- 
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Fig.3. AG 1 X 8 chromatography of mucopolysaccharide fragments after chondroitinase A, B and C digestion of dermatan sulphate 
Separation was carried out on 15 X 1.5 cm columns of AG 1 X 8 resin. The following samples were diluted and applied to the 
column: 5 rag of dermatan sulphate digested by chondroitinase A, B and C ( -A-) ;  the degradation products of the high molecular 
weight fraction of glycosaminoglycans from Maroteaux-Lamy urine ( -o - ) ;  A-4S-disaccharide ( -e - ) ;  and inorganic sulphate 
(- a-) .  Elution of each column was effected with a NaC1 gradient consisting of 10% NaC1 (120, ml; limit solution) and water 
(120 ml; receiving solution). 
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Fig.4. Mol. wt. determination of mucopolysaccharide 
fragment after chondroitinase A, B and C digestion of 
dermatan sulphate. The column (0.9 X 110 cm) was packed 
with Sephadex G-50 (fine) and standardized with: (1) nitro- 
catechol sulphate; (2) h-4S-disaccharide; (3) Dextran G 
10 000; (4) Heparin; (5) Dextran G 20 000; (6) Dermatan 
sulphate; (7) Chondroitin-6-sulphate. X °, Degradation 
product of dermatan sulphate:, X', desulphated degradation 
product. Deionized water was used for elution, 1.7 ml 
fractions were collected. 
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Fig.5. The circular dichroism spectra for dermatan sulphate, 
octasaccharide and n-4S-disaccharide. The circular dichroism 
(CD) spectra were recorded at room temperature on Cary 61 
spectropolarimeter in 0.005 M Tris-HC1 buffer pH 7.5. 
Dermatan sulphate ( -e- ) ;  octasaccharide (-~-);  A-4S- 
disaccharide (-o-) .  
tion VI. The reaction was carried out for 14 h at 37°C 
in 0.5 M acetate buffer, pH 5.8. The sulphate release 
changes either with increasing quantity of arylsul- 
phatase B (pI = 8.1) or the subfraction VI (pI = 6.0). 
In addition, the mol. wt. of the octasaccharide 
modified by arylsulphatase B and subfraction VI 
remained greater than 1000, indicating that the 
substrate was not greatly degraded. 
Subfraction II and VI, when combined, released 
only small quantities of sulphate (2-5%) from 
undegraded dermatan sulphate, A-4S-disaccharide, 
A-6S-disaccharide, galactosamine-4-sulphate or 
galactosamine-6-sulphate. The degradation product of 
glycosaminoglycans from Maroteaux-Lamy urine 
which eluted with 1.2 N NaC1 did not serve as 
substrate, while that eluted with 0.7 N NaCI was 
hydrolysed (35% of the sulphate was released, table 2). 
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Fig.6. U.v. spectra for dermatan sulphate and octasaccharide 
before and after desulphation. The u.v. spectra were recorded 
in 0.005 M Tris-HCl buffer pH 7.5. Dermatan sulphate ( -o-) ;  
octasaccharide b fore (-•-) and after desulphation (-o-) .  
Table 2 
Sulphate release from various ubstrates inthe presence of 
arylsulphatase B and subfraction VI (pH 6.0) 
Substrate Total amount 
of sulphate in 
the incubation 
mixture in/~g 
Percent of sulphate released 
after 14 h at 37°C in 0.5 M 
acetate buffer pH 5.8 
Arylsulphatase Subfraction 
B V1 
Subfraction VI 
and Arylsulpha- 
tase B 
Dermatan 
sulphate 50 0 4.4 5.0 
Mucopolysaccharide 
fragment from 
Maroteaux-Lamy 
urine 24 0 2.1 37.0 
Octasaccharide 48 1 1.3 76.0 
Nitrocatechol 
sulphate 196 92 0 92.0 
The reaction was carried out in the presence of 1.85 #g of arylsulphatase B and 4 #g protein of 
subfraction VI (pI 6.0.). 
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In addition, subfraction VI (pI = 6.0) did not 
contain/3-glucuronidase,/3-galactosidase, a- and 
/3-N-acetylhexosaminidase or a-iduronidase activity 
and lost its biological activity upon boiling. 
The requirement of two components for sulphate 
release from the natural substrate in vitro indicate 
the following: one of them may be responsible for 
the chemical conversion (arylsulphatase B), while 
the other component may modify the substrate or 
the enzymatic omponent in the reaction. 
The substrate requirements of enzymes capable 
of sulphate release from mucopolysaccharides 
depended on the enzyme source. Substrate for the 
placental system described herein appears to be very 
similar to that from rat liver [20]. 
However, contrary to current data that indicate 
that desulphation takes place from the non-reducing 
end of the sugar moiety, the data presented here 
(high sulphate release, 75%, and high mol. wt. of the 
modified product) support he suggestion of Matalon 
et al. [6] that the internal sulphate group might be 
released as well. 
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